Losartan is a drug used to treat high blood pressure. Losartan blocks the action of chemicals that make blood vessels constrict (get narrower). It is a type of angiotensin II receptor antagonist. Also called Cozaar and losartan potassium.
Preeclampsia may permanently change the blood vessels of women who experience the condition during pregnancy, boosting their lifelong risk for cardiovascular disease, according to Penn State researchers.
Results of a new study led by Johns Hopkins researchers offer new evidence for a strong link between angiotensin receptor autoantibodies and increased risk of frailty.
Massachusetts General Hospital investigators have discovered the mechanism by which obesity increases inflammation and desmoplasia - an accumulation of connective tissue - in the most common form of pancreatic cancer.
There's no getting around it: Simply getting around is a major issue for older adults.
"People are in nursing homes for two reasons, either they can't think or they can't walk," said Stephen Kritchevsky, Ph.D., director of the Sticht Center on Aging at Wake Forest Baptist Medical Center. North Carolina. "We're working very hard on the thinking part, and the walking part is equally important.
People with Alzheimer’s disease are helping with a ground-breaking government-funded trial but with new sites recently opened in the South West more people are being asked to take part in the study led by academics from the Universities of Bristol, Cambridge, Queen’s University Belfast and University College London, and hosted by North Bristol NHS Trust.
A new treatment for Marfan syndrome, a rare genetic disease that can lead to heart problems, works as well as the currently recommended medical therapy, beta blockers, according to an article in the New England Journal of Medicine.
An investigational treatment for Marfan syndrome is as effective as the standard therapy at slowing enlargement of the aorta, the large artery of the heart that delivers blood to the body, new research shows. The findings indicate a second treatment option for Marfan patients, who are at high risk of sudden death from tears in the aorta.
There are currently only two FDA-approved medications for the treatment of posttraumatic stress disorder (PTSD) in the United States. Both of these medications are serotonin uptake inhibitors. Despite the availability of these medications, many people diagnosed with PTSD remain symptomatic, highlighting the need for new medications for PTSD treatment.
Between 10 and 20 percent of all cases of epilepsy result from severe head injury, but a new drug promises to prevent post-traumatic seizures and may forestall further brain damage caused by seizures in those who already have epilepsy.
Computed tomography (CT) scans routinely taken to guide the treatment of pancreatic cancer may provide an important secondary benefit. According to new research from The University of Texas MD Anderson Cancer Center, the scans also reflect how well chemotherapy will penetrate the tumor, predicting the effectiveness of treatment.
Johns Hopkins pediatric cardiologist and geneticist Hal Dietz, M.D., has been awarded the first Harrington Prize for Innovation in Medicine for his work identifying the cause and a treatment for Marfan syndrome.
A common drug that is used to treat high blood pressure in the general population has been found to significantly reduce a dangerous and frequently fatal cardiac problem in patients with Marfan syndrome.
Newly published research by investigators at the Johns Hopkins Children's Center and the Johns Hopkins Institute of Genetic Medicine reveals that a faulty genetic pathway already known for its role in some connective tissue disorders is also a potent player in many types of allergies.
Two drugs, telmisartan and valsartan, which are used to reduce blood pressure in people with diabetes, are associated with a lower risk of hospitalization for heart attack, stroke or heart failure, according to a study published in CMAJ (Canadian Medical Association Journal).
Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2012.
A drug that protects the kidneys of patients with chronic kidney disease does not seem to provide the same benefit to kidney transplant recipients, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
The results of the first trial to administer the polypill on the basis of age alone has shown the largest reductions in blood pressure and cholesterol level of any polypill trial to date, researchers report.
Gout has been described by the Daily Mail as something, “usually associated with port-swilling, over-fed elderly men of the 19th century”. (1) Recent research carried out at the Boston University School of Medicine, however, has found that the incidence of gout in the US is on the rise. (2) Thus, the condition is clearly not something that only affects this stereotype.
Although observational studies have suggested that losartan, a drug used primarily for the treatment of hypertension, may be associated with an increased risk of death among patients with heart failure compared with other medications in the same class of drugs (angiotensin II receptor blockers [ARBs]), an analysis that included nearly 6,500 patients found that overall, use of losartan was not associated with increased all-cause death or cardiovascular death compared with use of the ARB candesartan, according to a study in the April 11 issue of JAMA.